We investigated the pharmacokinetics of epirubicin, an anthracycline derivative antibiotics, after intravenous (i.v.) bolus administration in rats. To analyze epirubicin levels in the plasma, bile, urine and tissue samples, we developed an high-performance liqid chromatography (HPLC)-based method which was validated for a pharmacokinetic study by suitable criteria. The plasma concentration of epirubicin after i.v. bolus administration was rapidly disappeared within 10 min from the blood circulation. The mean plasma half-lives at α phase (t1/2α) when administered at the dose of 2, 5, 10, 25 and 50 mg/kg were 2.14–2.61 min. The values of t1/2β at the corresponding doses increased two folds (from 150 to 291 min) with increasing doses. The CLt values significantly decreased with the increase in dose. In contrast, Vdss values increased about 1.5 times with the increase in dose from 2 to 50 mg/kg. Of the various tissues, epirubicin mainly distributed to the kidney, lung, heart and liver after i.v. bolus administration. The epirubicin concentrations in various tissues at 24 h after i.v. bolus administration were below 1.0 μg/g tissue. Epirubicin was excreted largely in the bile after i.v. bolus administration at the dose of 2, 10 and 50 mg/kg. The cumulative amount of epirubicin in the urine 72 h after dosage represented 20 % of the amount excreted in the bile 12 h after high dosage, indicating that i.v. administered epirubicin was mainly excreted in the bile. In conclusion, epirubicin was rapidly cleared from the blood circulation and transferred to tissues such as the kidney and liver 2 h after i.v. bolus administration. Moreover, the majority of epirubicin appears to be excreted in the bile by 12 h after i.v. bolus administration.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Arcamone FM (1998) From the pigments of the actinomycetes to third generation antitumor anthracyclines. Biochimie 80:201–206
Arcamone F, Cassinelli G, Fantini G, Grein A, Orezzi P, Pol C, Spalla C (1969) Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius. Biotechnol Bioeng 11:1101–1110
Berchem GJ, Ries F, Hanfelt J, Duhem C, Keipes M, Delagardelle C, Dicato M (1996) Epirubicin cardiotoxicity: a study comparing low- with high-dose-intensity weekly schedules. Support Care Cancer 4:308–312
Fujita H, Ogawa K, Tone H, Iguchi H, Shomura T, Murata S (1986) Pharmacokinetics of doxorubicin, (2″R)-4′-O-tetrahydropyranyl-adriamycin and aclarubicin. Jpn J Antibiot 39:1321–1336
Hong YS, Hwang CK, Hong SK, Kim YH, Lee JJ (1994) Molecular cloning and characterization of the aklavinone 11-hydroxylase gene of Streptomyces peucetius subsp. caesius ATCC 27952. J Bacteriol 176:7096–7101
Iguchi H, Seryu Y, Kiyosaki T, Hori S, Tone H, Oki T (1980) Studies on the absorption, excretion and distribution of aclacinomycin A: absorption, excretion and distribution of 14C- or 3H-aclacinomycin A in mice, rats and rabbits. Jpn J Antibiot 33:169–178
Kim HS, Hong YS, Kim YH, Yoo OJ, Lee JJ (1996) New anthracycline metabolites produced by the aklavinone 11-hydroxylase gene in Streptomyces galilaeus ATCC 31133. J Antibiot 49:355–360
Liang CH, Shiu LY, Chang LC, Sheu HM, Kuo KW (2007) Solamargine upregulation of Fas, downregulation of HER2, and enhancement of cytotoxicity using epirubicin in NSCLC cells. Mol Nutr Food Res 51:999–1005
Madduri K, Kennedy J, Rivola G, Inventi-Solari A, Filippini S, Zanuso G, Colombo AL, Gewain KM, Occi JL, Macneil DJ, Hutchinson CR (1998) Production of the antitumor drug epirubicin (4′-epidoxorubicin) and its precursor by a genetically engineered strain of Streptomyces peucetius. Nat Biotechnol 16:69–74
Maeda S, Miwa Y (2013) Multicomponent high-performance liquid chromatography/tandem mass spectrometry analysis of ten chemotherapeutic drugs in wipe samples. J Chromatogr B Analyt Technol Biomed Life Sci 15:921–922
Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56:185–229
Oki T, Kitamura I, Matsuzawa Y, Shibamoto N, Ogasawara T, Yoshimoto A, Inui T, Naganawa H, Takeuchi T, Umezawa H (1979) Antitumor anthracycline antibiotics, aclacinomycin a and analogues II. Structural determination. J Antibiot 32:801–819
Peng X, Chen B, Lim CC, Sawyer DB (1993) The cardiotoxicology of anthracycline chemotherapeutics: translating molecular mechanism into preventative medicine. Mol Interv 5:163–171
Robert J (1993) Epirubicin. Clinical pharmacology and dose-effect relationship. Drugs 45(Suppl 2):20–30
Sottani C, Poggi G, Quaretti P, Regazzi M, Montagna B, Quaquarini E, Imbriani M, Leoni E, Di Cesare P, Riccardi A, Bernardo G, Minoia C (2012) Serum pharmacokinetics in patients treated with transarterial chemoembolization (TACE) using two types of epirubicin-loaded microspheres. Anticancer Res 32:1769–1774
Weiss RB (1992) The anthracyclines: will we ever find a better doxorubicin? Semin Oncol 19:670–686
Yoo BI, Ahan KB, Kang MH, Moon DC, Kwon OS, Lee HS, Ryu JS, Kim TY, Song S, Chung YB (2005) HPLC analysis and pharmacokinetic characteristics of 11-hydroxyaclacinomycin X (ID-6105), a novel anthracycline, in rats and beagle dogs. Biol Pharm Bull 28:688–693
This work was supported by the research Grant of the Chungbuk National University in 2011. DH Shin, SH Park, OS Kwon, CW Park, K Han and YB Chung declare that they have no conflicts of interest.
About this article
Cite this article
Shin, D.H., Park, S.H., Kwon, OS. et al. Validation of high-performance liqid chromatography method to determine epirubicin and its pharmacokinetics after intravenous bolus administration in rats. Journal of Pharmaceutical Investigation 43, 243–249 (2013). https://doi.org/10.1007/s40005-013-0076-1